A novel 6-metabolite signature for prediction of clinical outcomes in type 2 diabetic patients undergoing percutaneous coronary intervention.

Wang, Xue-Bin; Cui, Ning-Hua; Liu, Xia'nan

Wang, Xue-Bin; Cui, Ning-Hua; Liu, Xia'nan.

Afiliación

Wang XB; Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Jianshe East Road No.1, Zhengzhou, 450000, Henan, China. xbwang2017@163.com.
Cui NH; Zhengzhou Key Laboratory of Children's Infection and Immunity, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450000, Henan, China.
Liu X; Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Jianshe East Road No.1, Zhengzhou, 450000, Henan, China.

Cardiovasc Diabetol ; 21(1): 126, 2022 07 04.

Article en En | MEDLINE | ID: mdl-35788230

Asunto(s)

Diabetes Mellitus Tipo 2; Intervención Coronaria Percutánea; Estudios de Casos y Controles; Diabetes Mellitus Tipo 2/diagnóstico; Diabetes Mellitus Tipo 2/etiología; Humanos; NAD; Intervención Coronaria Percutánea/efectos adversos; Estudios Prospectivos

Palabras clave

Clinical outcomes after PCI; Metabolomics; NAD metabolites; Prediction model; Type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Intervención Coronaria Percutánea Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cardiovasc Diabetol Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google